Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pharmacyl AB is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution is currently handled by 1 distinct examiner and 1 distinct art unit. The busiest examiner, ABDALHAMEED, MANAHIL MIRGHANI ALI, is assigned to 1 pending office action.
This examiner is the sole individual responsible for the company's current active office actions. The 1 distinct art unit indicates that the prosecution is concentrated in a specific technical division of the USPTO. Practitioners should note that having 1 pending office action under 1 distinct examiner creates a focused environment for negotiation.
The outcome of the 1 pending office action will be determined by the specific requirements of the 1 distinct art unit and the examiner's interpretation of the Biotechnology & Pharmaceuticals subject matter. Because the busiest examiner pending count is 1, the applicant can dedicate its full attention to the specific feedback provided by ABDALHAMEED, MANAHIL MIRGHANI ALI.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +38.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18630644 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | ABDALHAMEED, MANAHIL MIRGHANI ALI | 132d overdue |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18630644 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Non-Final OA | 132d overdue | Pending | Apr 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial